Bristol-Myers Squibb Company financials
Key figures from Bristol-Myers Squibb Company's filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $13.0B | $12.3B | +5.7% |
| Net income | $3.3B | $1.3B | +153.2% |
| Free cash flow | $3.1B | $3.6B | -13.2% |
| Gross margin | 71.3% | 72.5% | -1.2 pts |
| Operating margin | — | — | — |
| Net margin | 25.6% | 10.7% | +14.9 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $48.2B | $7.1B | 14.6% | $12.8B | $3.46 |
| FY Dec 2024 | $48.3B | -$8.9B | -18.5% | $13.9B | -$4.41 |
| FY Dec 2023 | $45.0B | $8.0B | 17.8% | $12.7B | $3.86 |
| FY Dec 2022 | $46.2B | $6.3B | 13.7% | $11.9B | $2.95 |
| FY Dec 2021 | $46.4B | $7.0B | 15.1% | $15.2B | $3.12 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.